Health and Happiness (H&H) International Holdings Limited logo

Health and Happiness (H&H) International Holdings Limited

1112.HK

HKSEConsumer DefensivePackaged Foods

Latest quote

HK$14.96

−HK$0.50 · -3.23%

Aug 24, 10:59 AM HKT

1112.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

As an investment holding entity, Health and Happiness (H&H) International Holdings Limited specializes in the global production and distribution of nutritional and care products designed for families and infants. Its offerings are categorized into several key segments. The Infant Formulas division crafts nutritional formulas for children up to age seven, alongside specialized milk products for pregnant and breastfeeding women. The Probiotic Supplements division provides various forms of probiotics, including sachets, capsules, and tablets, catering to the needs of babies, children, and expecting mothers. Within its Adult Nutrition and Care Products segment, H&H develops and markets a range of items such as vitamins, general health supplements, skincare solutions, and sports nutrition for grown-ups. Complementing its infant offerings, the Other Pediatric Products segment focuses on manufacturing dried baby foods, additional nutritional supplements, and general baby care items. Furthermore, its Pet Nutrition and Care segment creates pet food, health-enhancing supplements, and bone broth products for animals. Beyond these core product lines, the company's activities extend to research, development, and processing of diverse ingredients like meat, fruit, and vegetable powders, as well as candies. It actively researches, develops, manufactures, and sells specialized nutritional foods, manages the marketing and distribution of organic baby foods, and handles the wholesale, retail, import, and export of infant nutritional and personal care products. H&H also engages in the trading and sale of adult vitamins, health supplements, probiotic skincare, and sports nutrition items, while offering online sales platforms, software and IT solutions, and packaging services. Its extensive product portfolio is marketed under well-known brands such as Biostime, Swisse, Aurelia, Zesty Paws, Solid Gold, Dodie, Good Gout, Aurelia London, and CBII. Established in 1999, the company adopted its current name, Health and Happiness (H&H) International Holdings Limited, in June 2017, having previously operated as Biostime International Holdings Limited. Headquartered in Quarry Bay, Hong Kong, H&H functions as a subsidiary of Biostime Pharmaceuticals (China) Limited.

Industry
Packaged Foods
Sector
Consumer Defensive
Headquarters
HK
CEO
Akash Bedi
Listed since
Dec 17, 2010
Employees
2,758

Market position

Day range

Current HK$14.96

52-week range

Current HK$14.96

Open
HK$15.27
Previous close
HK$15.46
Volume
322K
0.14× average
Average volume
2.37M
Average daily volume
Market cap
9.66B HKD
Beta
1.36
Market reference 1
50-day average
HK$13.6994
+9.20% above average
200-day average
HK$13.644
+9.65% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
14.93B CNY
P/E (TTM)
42.75×
P/B (TTM)
1.37×
P/S (TTM)
0.58×
EV / EBITDA
8.4×
Earnings yield
2.59%
Free cash flow yield
12.52%
Dividend yield
2.34%

Profitability & efficiency

Gross margin
62.45%
Operating margin
11.63%
Net margin
1.37%
Return on equity
3.27%
Return on assets
1.01%
Return on invested capital
3.66%

Financial health

Debt / equity
1.51×
Current ratio
1.15×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends69%44%19%-7%Gross margin, FY2021: 62.76%Gross margin, FY2022: 60.30%Gross margin, FY2023: 60.84%Gross margin, FY2024: 60.65%Gross margin, FY2025: 62.45%Operating margin, FY2021: 13.09%Operating margin, FY2022: 12.58%Operating margin, FY2023: 13.16%Operating margin, FY2024: 12.04%Operating margin, FY2025: 11.63%Net margin, FY2021: 4.40%Net margin, FY2022: 4.79%Net margin, FY2023: 4.18%Net margin, FY2024: -0.41%Net margin, FY2025: 1.37%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 62.76%. Gross margin FY2022 60.30%. Gross margin FY2023 60.84%. Gross margin FY2024 60.65%. Gross margin FY2025 62.45%. Operating margin FY2021 13.09%. Operating margin FY2022 12.58%. Operating margin FY2023 13.16%. Operating margin FY2024 12.04%. Operating margin FY2025 11.63%. Net margin FY2021 4.40%. Net margin FY2022 4.79%. Net margin FY2023 4.18%. Net margin FY2024 -0.41%. Net margin FY2025 1.37%.

Income trends

Revenue

14.35B CNY+9.97%

Operating income

1.67B CNY+6.22%

Net income

196.14M CNY+249.86M CNY
Income trends across reported periods15.79B CNY10.03B CNY4.27B CNY−1.49B CNYRevenue, FY2021: 11.55B CNYRevenue, FY2022: 12.78B CNYRevenue, FY2023: 13.93B CNYRevenue, FY2024: 13.05B CNYRevenue, FY2025: 14.35B CNYOperating income, FY2021: 1.51B CNYOperating income, FY2022: 1.61B CNYOperating income, FY2023: 1.83B CNYOperating income, FY2024: 1.57B CNYOperating income, FY2025: 1.67B CNYNet income, FY2021: 508.48M CNYNet income, FY2022: 611.78M CNYNet income, FY2023: 581.85M CNYNet income, FY2024: −53.72M CNYNet income, FY2025: 196.14M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 11.55B CNY. Revenue FY2022 12.78B CNY. Revenue FY2023 13.93B CNY. Revenue FY2024 13.05B CNY. Revenue FY2025 14.35B CNY. Operating income FY2021 1.51B CNY. Operating income FY2022 1.61B CNY. Operating income FY2023 1.83B CNY. Operating income FY2024 1.57B CNY. Operating income FY2025 1.67B CNY. Net income FY2021 508.48M CNY. Net income FY2022 611.78M CNY. Net income FY2023 581.85M CNY. Net income FY2024 −53.72M CNY. Net income FY2025 196.14M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue14.35B CNY13.05B CNY13.93B CNY12.78B CNY11.55B CNY
Cost of goods sold5.39B CNY5.14B CNY5.45B CNY5.07B CNY4.3B CNY
Gross profit8.96B CNY7.92B CNY8.47B CNY7.7B CNY7.25B CNY
Research and development216.2M CNY242.98M CNY206.08M CNY158.19M CNY143.96M CNY
Selling, general, and administrative7.08B CNY6.35B CNY6.43B CNY5.96B CNY5.67B CNY
Operating expenses7.29B CNY6.34B CNY6.64B CNY5.93B CNY5.63B CNY
Interest income17.22M CNY20.57M CNY30.23M CNY20.02M CNY11.88M CNY
Interest expense685.55M CNY869.87M CNY807.61M CNY530.29M CNY263.74M CNY
Depreciation and amortization216.77M CNY300.99M CNY302.25M CNY311.28M CNY305.48M CNY
Operating income1.67B CNY1.57B CNY1.83B CNY1.61B CNY1.51B CNY
Net income196.14M CNY−53.72M CNY581.85M CNY611.78M CNY508.48M CNY

Company facts updated Aug 24, 2026.

1112.HK peers

ETFs holding 1112.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 1112.HK

research.disclaimer